Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: UK Sets Up ‘Pioneering’ Vaccines Lab, MSF Piles Pressure On TRIPS Waiver Holdouts

Executive Summary

The UK has OKd trials of a new AI-derived combination treatment from Canadian firm Skymount Medical. Health Canada has approved Novavax’s COVID-19 vaccine, and Australia has given the go-ahead to use Moderna’s Spikevax in children aged six years and up.

You may also be interested in...



Co-Inventor Of mRNA Tech Goes After Sickle Cell Anemia

After a chance encounter at a photocopy machine brewed the recipe for Pfizer and Moderna’s success with mRNA vaccines, Dr Drew Weissman has set sights on developing a single-injection therapy for sickle cell anemia.

Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.

Bigger Trials, More RWE Needed for Future Crisis Response, Say EU Regulators

A report from the EU medicines regulatory network looks at what was done well in the response to the COVID-19 pandemic, and what needs to be improved if we are to be better prepared next time. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel